Multiple Myeloma | Maryland Oncology Hematology Multiple Myeloma – Maryland Oncology Hematology

Trial ID BGB-11417-105

NCT04973605
clinicaltrials.gov ID
Phase Ib/II

Trial ID 20285

NCT04782687
clinicaltrials.gov ID
USOR ID: 20285 Phase II
A Phase II Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor for Patients with Newly Diagnosed Multiple Myeloma

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology